Blockade of miR-150 Maturation by MLL-Fusion/MYC/LIN-28 Is Required for MLL-Associated Leukemia

Cancer Cell

Volumn 22, Issue 4, 2012, Pages 524-535

  Jiang, Xi ^a   Huang, Hao ^a   Li, Zejuan ^a   Li, Yuanyuan ^a   Wang, Xiao ^b   Gurbuxani, Sandeep ^c   Chen, Ping ^a   He, Chunjiang ^a   You, Dewen ^d   Zhang, Shuodan ^a   Wang, Jinhua ^a   Arnovitz, Stephen ^a   Elkahloun, Abdel ^e   Price, Colles ^a   Hong, Gia Ming ^a   Ren, Haomin ^a   Kunjamma, Rejani B ^a   Neilly, Mary Beth ^a   Matthews, Jonathan M ^a   Xu, Mengyi ^a   Larson, Richard A ^a   Le Beau, Michelle M ^a   Slany, Robert K ^f   Liu, Paul P ^e   Lu, Jun ^g   Zhang, Jiwang ^d   He, Chuan ^b   Chen, Jianjun ^a   more..

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; HYBRID PROTEIN; MICRORNA; MICRORNA 150; MIXED LINEAGE LEUKEMIA PROTEIN; MYC PROTEIN; PROTEIN LIN28; RNA BINDING PROTEIN; RNA PRECURSOR; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; FUSION GENE; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LEUKEMOGENESIS; LIN28 GENE; MIXED LINEAGE LEUKEMIA GENE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE MYB; ONCOGENE MYC; PATHOGENESIS; PRIORITY JOURNAL; RNA PROCESSING; RNA SYNTHESIS; SIGNAL TRANSDUCTION;

EID: 84867595341     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.08.028     Document Type: Article

References (50)

1. Armstrong S.A., Staunton J.E., Silverman L.B., Pieters R., den Boer M.L., Minden M.D., Sallan S.E., Lander E.S., Golub T.R., Korsmeyer S.J. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 2002, 30:41-47.
2. Armstrong S.A., Kung A.L., Mabon M.E., Silverman L.B., Stam R.W., Den Boer M.L., Pieters R., Kersey J.H., Sallan S.E., Fletcher J.A., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003, 3:173-183.
3. Behm F.G., Raimondi S.C., Frestedt J.L., Liu Q., Crist W.M., Downing J.R., Rivera G.K., Kersey J.H., Pui C.H. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996, 87:2870-2877.
4. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
5. Bullinger L., Döhner K., Bair E., Fröhling S., Schlenk R.F., Tibshirani R., Döhner H., Pollack J.R. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 2004, 350:1605-1616.
6. Chang T.C., Zeitels L.R., Hwang H.W., Chivukula R.R., Wentzel E.A., Dews M., Jung J., Gao P., Dang C.V., Beer M.A., et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc. Natl. Acad. Sci. USA 2009, 106:3384-3389.
7. Chen J., Odenike O., Rowley J.D. Leukaemogenesis: more than mutant genes. Nat. Rev. Cancer 2010, 10:23-36.
8. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., Robson S.C., Chung C.W., Hopf C., Savitski M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
9. Faber J., Krivtsov A.V., Stubbs M.C., Wright R., Davis T.N., van den Heuvel-Eibrink M., Zwaan C.M., Kung A.L., Armstrong S.A. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009, 113:2375-2385.
10. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
11. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., Hammond S.M. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
12. Heo I., Joo C., Cho J., Ha M., Han J., Kim V.N. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol. Cell 2008, 32:276-284.
13. Hess J.L., Bittner C.B., Zeisig D.T., Bach C., Fuchs U., Borkhardt A., Frampton J., Slany R.K. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood 2006, 108:297-304.
14. Hoffman B., Amanullah A., Shafarenko M., Liebermann D.A. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 2002, 21:3414-3421.
15. Jin S., Zhao H., Yi Y., Nakata Y., Kalota A., Gewirtz A.M. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J. Clin. Invest. 2010, 120:593-606.
16. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7:823-833.
17. Krivtsov A.V., Feng Z., Lemieux M.E., Faber J., Vempati S., Sinha A.U., Xia X., Jesneck J., Bracken A.P., Silverman L.B., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
18. Li L., Piloto O., Kim K.T., Ye Z., Nguyen H.B., Yu X., Levis M., Cheng L., Small D. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. Br. J. Haematol. 2007, 137:64-75.
19. Li Y.J., Zhang Y.X., Wang P.Y., Chi Y.L., Zhang C., Ma Y., Lv C.J., Xie S.Y. Regression of A549 lung cancer tumors by anti-miR-150 vector. Oncol. Rep. 2012, 27:129-134.
20. Li Z., Huang H., Chen P., He M., Li Y., Arnovitz S., Jiang X., He C., Hyjek E., Zhang J., et al. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat. Commun. 2012, 3:688.
21. Li Z., Lu J., Sun M., Mi S., Zhang H., Luo R.T., Chen P., Wang Y., Yan M., Qian Z., et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc. Natl. Acad. Sci. USA 2008, 105:15535-15540.
22. Lu J., Guo S., Ebert B.L., Zhang H., Peng X., Bosco J., Pretz J., Schlanger R., Wang J.Y., Mak R.H., et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev. Cell 2008, 14:843-853.
23. Mi S., Li Z., Chen P., He C., Cao D., Elkahloun A., Lu J., Pelloso L.A., Wunderlich M., Huang H., et al. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc. Natl. Acad. Sci. USA 2010, 107:3710-3715.
24. Milne T.A., Dou Y., Martin M.E., Brock H.W., Roeder R.G., Hess J.L. MLL associates specifically with a subset of transcriptionally active target genes. Proc. Natl. Acad. Sci. USA 2005, 102:14765-14770.
25. Milne T.A., Martin M.E., Brock H.W., Slany R.K., Hess J.L. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 2005, 65:11367-11374.
26. Newman M.A., Hammond S.M. Emerging paradigms of regulated microRNA processing. Genes Dev. 2010, 24:1086-1092.
27. Newman M.A., Thomson J.M., Hammond S.M. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 2008, 14:1539-1549.
28. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
29. Popovic R., Riesbeck L.E., Velu C.S., Chaubey A., Zhang J., Achille N.J., Erfurth F.E., Eaton K., Lu J., Grimes H.L., et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 2009, 113:3314-3322.
30. Ramsay R.G., Barton A.L., Gonda T.J. Targeting c-Myb expression in human disease. Expert Opin. Ther. Targets 2003, 7:235-248.
31. Rowley J.D. Chromosomal translocations: revisited yet again. Blood 2008, 112:2183-2189.
32. Schreiner S., Birke M., García-Cuéllar M.P., Zilles O., Greil J., Slany R.K. MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation. Cancer Res. 2001, 61:6480-6486.
33. Shankar D.B., Li J., Tapang P., Owen McCall J., Pease L.J., Dai Y., Wei R.Q., Albert D.H., Bouska J.J., Osterling D.J., et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007, 109:3400-3408.
34. Siomi H., Siomi M.C. Posttranscriptional regulation of microRNA biogenesis in animals. Mol. Cell 2010, 38:323-332.
35. Somervaille T.C., Matheny C.J., Spencer G.J., Iwasaki M., Rinn J.L., Witten D.M., Chang H.Y., Shurtleff S.A., Downing J.R., Cleary M.L. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 2009, 4:129-140.
36. Srivastava S.K., Bhardwaj A., Singh S., Arora S., Wang B., Grizzle W.E., Singh A.P. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis 2011, 32:1832-1839.
37. Stubbs M.C., Armstrong S.A. FLT3 as a therapeutic target in childhood acute leukemia. Curr. Drug Targets 2007, 8:703-714.
38. Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J. Hematol. Oncol. 2011, 4:13.
39. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 2001, 98:5116-5121.
40. Viswanathan S.R., Daley G.Q., Gregory R.I. Selective blockade of microRNA processing by Lin28. Science 2008, 320:97-100.
41. Wang G.G., Pasillas M.P., Kamps M.P. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. Blood 2005, 106:254-264.
42. Wu Q., Jin H., Yang Z., Luo G., Lu Y., Li K., Ren G., Su T., Pan Y., Feng B., et al. MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem. Biophys. Res. Commun. 2010, 392:340-345.
43. Xiao C., Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009, 136:26-36.
44. Xiao C., Calado D.P., Galler G., Thai T.H., Patterson H.C., Wang J., Rajewsky N., Bender T.P., Rajewsky K. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007, 131:146-159.
45. Yao Q., Nishiuchi R., Li Q., Kumar A.R., Hudson W.A., Kersey J.H. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin. Cancer Res. 2003, 9:4483-4493.
46. Yu B.D., Hess J.L., Horning S.E., Brown G.A., Korsmeyer S.J. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995, 378:505-508.
47. Zeisig B.B., Schreiner S., García-Cuéllar M.P., Slany R.K. Transcriptional activation is a key function encoded by MLL fusion partners. Leukemia 2003, 17:359-365.
48. Zeisig B.B., Milne T., García-Cuéllar M.P., Schreiner S., Martin M.E., Fuchs U., Borkhardt A., Chanda S.K., Walker J., Soden R., et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol. Cell. Biol. 2004, 24:617-628.
49. Zhang J., Luo N., Luo Y., Peng Z., Zhang T., Li S. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int. J. Oncol. 2012, 40:747-756.
50. Zuber J., Rappaport A.R., Luo W., Wang E., Chen C., Vaseva A.V., Shi J., Weissmueller S., Fellmann C., Taylor M.J., et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011, 25:1628-1640.